Wanbury gets Certificate of Suitability for cough relief medicine in Europe

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-09-09T15:01:58+05:30 | Updated On 9 Sept 2024 3:01 PM IST

Maharashtra: Wanbury Limited has announced that it has been awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its Dextromethorphan active pharmaceutical ingredient (API), antitussive (cough) medicine.

The global formulation market for Dextromethorphan is valued at USD 2,500 million for FY24, having grown by 7% over the past year. "With the CEP certification, Wanbury is well positioned to initiate the commercial sales of this product in European markets," the Compamy stated in a BSE filing.

Read also: Wanbury ropes in Prakash Venkatraman as President of API business

Wanbury Limited has a presence in API global market and domestic branded Formulation. Wanbury strength lies in Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India Formulation presence. The Company has a basket of over 13 API products. It has the larger customer base in Europe & US for Tramadol & Setraline (API).The Company has two US-FDA approved multi-product API facilities and one plant under operation for semi-regulated markets. It has pan-India presence in ethical formulations with a portfolio of close to 70 brands.

wanburywanbury newsdextromethorphan

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751